Press Releases

Our latest news and press releases

Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement

Read more

Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq

Read more

Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases

Read more

Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities

Read more

Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL

Read more

Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML

Read more

Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022

Read more

Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022

Read more

Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)

Read more

Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022

Read more